Overview

• Linda Yaccarino officially became CEO of eMed Population Health on August 5, moving from X after a two-year tenure and drawing on her decade at NBCUniversal
• She will leverage her expertise in digital revenue and brand partnerships to scale employer and government payer programs for GLP-1 weight-loss and diabetes therapies
• EMed, founded in 2020 as a COVID-19 diagnostics provider, has pivoted to managing GLP-1 treatments through live, on-demand telehealth visits
• The company partners with employers and government payers to overcome coverage barriers and claims it can cut treatment costs by up to 50%
• Telehealth platforms offering GLP-1 drugs are facing intensified scrutiny over patient safety standards, marketing practices and regulatory oversight gaps